Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Ovarian cancer at ESMO 2024: PRIMA and ATHENA

Jean Emmanuel Kurtz • 16 Sep 2024
ESMO 2024
Gynecological Cancer Ovarian Cancer Rucaparib
ATHENA PRIMA

Jean Emmanuel Kurtz, MD, PhD, University of Strasbourg, Strasbourg, France, gives an overview of his highlights in ovarian cancer at the European Society for Medical Oncology (ESMO) 2024 Congress. The PRIMA trial (NCT02655016) failed to reach its primary endpoint, and the ATHENA trial (NCT03522246) indicated that the combination of immunotherapy and rucaparib was ineffective. This interview took place at the ESMO 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jean Emmanuel Kurtz

ATALANTE: 5-year OS results of atezolizumab in platinum-sensitive ovarian cancer
1:14
ATALANTE: 5-year OS results of atezolizumab in platinum-sensitive ovarian cancer
Jean Emmanuel Kurtz • 16 Sep 2024
Analysis of the 5-year OS findings from the ATALANTE trial in ovarian cancer
0:45
Analysis of the 5-year OS findings from the ATALANTE trial in ovarian cancer
Jean Emmanuel Kurtz • 16 Sep 2024
IBI354 & TORL-1-23: novel HER-2 and CLDN6 targeting ADCs in gynecological cancers
1:05
IBI354 & TORL-1-23: novel HER-2 and CLDN6 targeting ADCs in gynecological cancers
Jean Emmanuel Kurtz • 16 Sep 2024

Related Videos

Selective PARP1 inhibitors show promise in ovarian and breast cancer
1:13
Selective PARP1 inhibitors show promise in ovarian and breast cancer
Martin Hojgaard • 29 May 2026
EIK1003-001: Phase I/II trial of EIK1003 in PROC and HER- breast cancer
0:55
EIK1003-001: Phase I/II trial of EIK1003 in PROC and HER- breast cancer
Martin Hojgaard • 29 May 2026
BLUESTAR: puxitatug samrotecan safety & efficacy in endometrial or ovarian cancer
1:28
BLUESTAR: puxitatug samrotecan safety & efficacy in endometrial or ovarian cancer
Linda Mileshkin • 30 May 2026
The future targeted therapies and ADCs in metastatic endometrial cancer
3:46
The future targeted therapies and ADCs in metastatic endometrial cancer
Ka Yu Tse • 17 Dec 2025
The content of VJOncology is intended for healthcare professionals